From Our 2012 Archives
New 1-a-Day HIV Treatment Approved
'Quad' Drug Stribild Is 3rd Once-Daily HIV Pill
By Daniel J. DeNoon
Reviewed by Louise Chang, MD
Aug. 28, 2012 -- The FDA has approved Stribild, the much anticipated once-daily "quad" HIV pill from Gilead Sciences.
The drug combines same two HIV drugs in Truvada, plus elvitegravir, a new HIV drug that attacks HIV in a different way. The fourth component, also new, boosts elvitegravir.
It's the third all-in-one, once-a-day HIV pill. The others are Atripla from Gilead and Bristol Myers, approved in 2006, and Complera from Gilead and Janssen, approved in 2011.
"Over the past decade, co-formulated HIV medicines have simplified therapy for many patients and have become standard of care," Paul Sax, MD, of Brigham and Women's Hospital, says in a Gilead news release.
Stribild is intended for people who have never taken HIV drugs. It should be taken with food.
Stribild carries a "black box" safety warning. In rare cases, the drug causes a buildup of lactic acid in the blood. It can also cause severe liver problems. Both of these side effects can be deadly.
More common side effects include nausea and diarrhea.
SOURCES: News release, FDA. News release, Gilead Sciences Inc. FDA web site.